FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kenneth Sommerville

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Physiology

Cognition

Co-author Network

Publications

TOP 3
Kerri A Schoedel; Kenneth W Sommerville; Almasa Bass; Nancy Chen; Janice Y Faulknor; Glenn C Pixton; Robert L Rolleri; Edward Sellers
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Almasa Bass; Mark Leibowitz; Glenn C Pixton; Kenneth W Sommerville; Jeffrey G Stark; Cynthia A Zamora; Robert Rolleri
Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Wolfgang H Oertel; Heike Benes; Diego Garcia-Borreguero; Peter Geisler; Birgit Högl; Bernd Saletu; Claudia Trenkwalder; Kenneth W Sommerville; Erwin Schollmayer; Ralf Kohnen; Karin Stiasny-Kolster
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kenneth Sommerville (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Kerri A Schoedel; Kenneth W Sommerville; Almasa Bass; Nancy Chen; Janice Y Faulknor; Glenn C Pixton; Robert L Rolleri; Edward Sellers
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Journal of opioid management 2012;8(5):315-27.
2012: Almasa Bass; Mark Leibowitz; Glenn C Pixton; Kenneth W Sommerville; Jeffrey G Stark; Cynthia A Zamora; Robert Rolleri
Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Clinical therapeutics 2012;34(7):1601-12.
2008: Wolfgang H Oertel; Heike Benes; Diego Garcia-Borreguero; Peter Geisler; Birgit Högl; Bernd Saletu; Claudia Trenkwalder; Kenneth W Sommerville; Erwin Schollmayer; Ralf Kohnen; Karin Stiasny-Kolster
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
Sleep medicine 2008;9(3):228-39.
2006: Kenneth W Sommerville
Bioequivalence in development of antiepileptic drugs.
Epilepsy research 2006;68(1):82-5.
2005: Werner M Güldenpfennig; Kathryn H Poole; Kenneth W Sommerville; Babak Boroojerdi
Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
Clinical neuropharmacology 2005;28(3):106-10.
2003: Kenneth W Sommerville; Sandeep Dutta; Victor Biton; Yiming Zhang; James C Cloyd; Basim M Uthman
Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.
Clinical drug investigation 2003;23(10):661-70.
2003: R Eugene Ramsay; D Cantrell; Stephen D Collins; J K Walch; DK Naritoku; James C Cloyd; Kenneth W Sommerville
Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy.
Epilepsy research 2003;52(3):189-201.
2002: John M Pellock; B Joseph Wilder; Roger Deaton; Kenneth W Sommerville
Acute pancreatitis coincident with valproate use: a critical review.
Epilepsia 2002;43(11):1421-4.
2002: Manon Thibault; Warren T Blume; Jean-Marc Saint-Hilaire; Rafik Zakhari; Kenneth W Sommerville
Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures.
Epilepsy research 2002;50(3):243-9.
2002: Frederick G Freitag; Stephen D Collins; H A Carlson; Jerome Goldstein; Joel R Saper; Stephen Silberstein; Ninan T Mathew; Paul Winner; R Deaton; Kenneth W Sommerville
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.
Neurology 2002;58(11):1652-9.
2002: J Chris Sackellares; Gregory Krauss; Kenneth W Sommerville; Roger Deaton
Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment.
Epilepsia 2002;43(4):394-8.
2002: Sandeep Dutta; Yiming Zhang; Daniel S Selness; Lillian L Lee; Laura A Williams; Kenneth W Sommerville
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
Epilepsy research 2002;49(1):1-10.
2001: Shlomo Shinnar; A T Berg; David Treiman; W A Hauser; D C Hesdorffer; J Chris Sackellares; Ilo E Leppik; M Sillanpaa; Kenneth W Sommerville
Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons.
Epilepsia 2001;42(3):372-9.
2000: Carl B Dodrill; JL Arnett; Roger Deaton; G T Lenz; Kenneth W Sommerville
Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.
Epilepsy research 2000;42(2-3):123-32.
2000: R Edward Hogan; Mary E Bertrand; Roger Deaton; Kenneth W Sommerville
Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin.
Epilepsy research 2000;41(1):23-8.
1999: Ilo E Leppik; L Gram; Roger Deaton; Kenneth W Sommerville
Safety of tiagabine: summary of 53 trials.
Epilepsy research 1999;33(2-3):235-46.
1998: Emil Samara; Linda E Gustavson; Tawakol A El-Shourbagy; Charles S Locke; G Richard Granneman; Kenneth W Sommerville
Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.
Epilepsia 1998;39(8):868-73.
1998: Linda E Gustavson; Kenneth W Sommerville; SW Boellner; GF Witt; HJ Guenther; G Richard Granneman
Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
American journal of therapeutics 1998;5(2):73-9.
1998: Linda E Gustavson; A Cato; SW Boellner; G X Cao; JX Qian; HJ Guenther; Kenneth W Sommerville
Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
American journal of therapeutics 1998;5(1):9-16.
1998: Carl B Dodrill; JL Arnett; VS Shu; G C Pixton; G T Lenz; Kenneth W Sommerville
Effects of tiagabine monotherapy on abilities, adjustment, and mood.
Epilepsia 1998;39(1):33-42.
1998: Basim M Uthman; A James Rowan; P A Ahmann; Ilo E Leppik; Steven C Schachter; Kenneth W Sommerville; VS Shu
Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial.
Archives of neurology 1998;55(1):56-62.
1997: Rajesh C Sachdeo; R F Leroy; Gregory Krauss; M E Drake; P M Green; Ilo E Leppik; VS Shu; G L Ringham; Kenneth W Sommerville
Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.
Archives of neurology 1997;54(5):595-601.
1997: Linda E Gustavson; SW Boellner; G Richard Granneman; JX Qian; HJ Guenther; Tawakol A El-Shourbagy; Kenneth W Sommerville
A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.
Neurology 1997;48(4):1032-7.
1997: Carl B Dodrill; JL Arnett; Kenneth W Sommerville; VS Shu
Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy.
Neurology 1997;48(4):1025-31.
1995: Carl B Dodrill; JL Arnett; Kenneth W Sommerville; N M Sussman
Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.
Epilepsia 1995;36(2):164-73.
1993: Carl B Dodrill; JL Arnett; Kenneth W Sommerville; N M Sussman
Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.
Neurology 1993;43(12):2501-7.
1986: R B Tenser; Kenneth W Sommerville; J G Mummaw; R J Frisque
Isolation of JC virus capsomer-like structures from progressive multifocal leukoencephalopathy brain.
Journal of the neurological sciences 1986;72(2-3):243-54.